Post-transplant erythroid engraftment in myelofibrosis

Current understanding

To be populated as evidence accumulates.

2026-06-03 — Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant: An early-phase HBOT trial in allo-PBSC for MF and related myeloid malignancies includes engraftment and neutrophil recovery endpoints, offering a mechanistically distinct (tissue oxygenation) adjunct to luspatercept- and momelotinib-based approaches to post-transplant hematopoietic recovery. (novelty: 4)
2026-03-31 — Momelotinib During and After HCT in Myelofibrosis: cross-connection with peritransplant-momelotinib: Momelotinib’s ACVR1/hepcidin-axis activity makes peri-transplant dosing mechanistically relevant to post-transplant erythroid recovery, potentially overlapping with luspatercept’s role for poor erythroid engraftment. (novelty: 3)
2026-04-20 — Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis: Prospective multicenter RCT planned to evaluate luspatercept (TGF-β superfamily modulator) for prevention of poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate-to-severe MF — first randomized trial design targeting this complication and introducing TGF-β pathway modulation (distinct from JAK inhibition) into peri-transplant MF management. (novelty: 4)